Latest News for ORYZF
MADRID and CAMBRIDGE, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today reported financial results for the twelve months ended December 31, 2025 and provided a corporate update on recent developments.
MADRID and CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A.
MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the results of voting at the Extraordinary General Shareholders' Meeting held last Friday in Madrid. A total of 33,581,589 of the Company's issued and outstanding voting rights (representing 37.7938% of the…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ORYZF.
Senate Trading
No Senate trades found for ORYZF.
U.S. House Trading
No House trades found for ORYZF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.